DR. ANTHONY P HEANEY, M.D.
Medical Practice in Los Angeles, CA
License number
California A92084
Category
Medical Practice
Type
Specialist
Address
Address
8700 Beverly Blvd., Los Angeles, CA 90048
Phone
(310) 967-1884
(310) 967-1744 (Fax)
(310) 967-1744 (Fax)
Personal information
See more information about ANTHONY P HEANEY at radaris.comName
Address
Phone
2871 Forrester Dr, Los Angeles, CA 90064
2016 Greenfield Ave, Los Angeles, CA 90025
2871 Forrester Dr, Los Angeles, CA 90064
3275 Sepulveda Blvd, Los Angeles, CA 90034
Organization information
See more information about ANTHONY P HEANEY at bizstanding.comUcla Dept-Medicine Professional Group - Anthony P Heaney MD
200 Ucla Medical Plz #530, Los Angeles, CA 90095
Categories:
Endocrinology & Metabolism Physicians & Surgeons, Internal Medicine Physicians & Surgeons
Phone:
(310) 825-7922 (Phone)
Professional information
See more information about ANTHONY P HEANEY at trustoria.com
Dr. Anthony P Heaney, Los Angeles CA - MD (Doctor of Medicine)
Dr. Anthony P Heaney, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism
Address:
200 Medical Plz Way SUITE 530, Los Angeles 90095
(310) 825-7922 (Phone)
Gonda Diabetes Center
200 Ucla Medical Plz SUITE 530, Los Angeles 90095
(310) 825-7922 (Phone)
(310) 825-7922 (Phone)
Gonda Diabetes Center
200 Ucla Medical Plz SUITE 530, Los Angeles 90095
(310) 825-7922 (Phone)
Languages:
English, Chinese, Russian, Spanish, Tagalog
Hospitals:
200 Medical Plz Way SUITE 530, Los Angeles 90095
Gonda Diabetes Center
200 Ucla Medical Plz SUITE 530, Los Angeles 90095
Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles 90095
Gonda Diabetes Center
200 Ucla Medical Plz SUITE 530, Los Angeles 90095
Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles 90095
Education:
Medical School
The Queen's University Of Belfast, College Of Medicine and Health Sciences
Graduated: 1986
The Queen's University Of Belfast, College Of Medicine and Health Sciences
Graduated: 1986
Anthony Patrick Heaney, Los Angeles CA
Anthony Patrick Heaney, Los Angeles CA
Specialties:
Internal Medicine, Endocrinology, Diabetes & Metabolism, Endocrinology and Metabolism
Work:
Ucla Medical Group-W LA
200 Ucla Medical Plz, Los Angeles, CA 90095
200 Ucla Medical Plz, Los Angeles, CA 90095
Education:
The Queen's University Of Belfast (1987)
Anthony Patrick Heaney, West Hollywood CA
Anthony Patrick Heaney, West Hollywood CA
Specialties:
Endocrinologist
Address:
8700 Beverly Blvd, West Hollywood, CA 90048
Methods Of Using Pituitary Tumor Transforming Gene (Pttg) Carboxy-Terminal Peptides To Inhibit Neoplastic Cellular Proliferation And/Or Transformation Of Breast And Ovarian Cells
Methods Of Using Pituitary Tumor Transforming Gene (Pttg) Carboxy-Terminal Peptides To Inhibit Neoplastic Cellular Proliferation And/Or Transformation Of Breast And Ovarian Cells
US Patent:
2003001, Jan 23, 2003
Filed:
Dec 4, 2000
Appl. No.:
09/730469
Inventors:
Anthony Heaney - Los Angeles CA, US
Gregory Horwitz - Calabasas CA, US
Xun Zhang - Malden MA, US
Shlomo Melmed - Los Angeles CA, US
Gregory Horwitz - Calabasas CA, US
Xun Zhang - Malden MA, US
Shlomo Melmed - Los Angeles CA, US
International Classification:
A61K048/00, A61K038/16
US Classification:
514/044000, 514/012000, 424/093210
Abstract:
Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian breast or ovarian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C), which has the ability to regulate endogenous pituitary tumor transforming gene (PTTG) expression and/or function in a dominant negative manner. In some embodiments, the invention is directed to gene-based treatments that deliver PTTG-C-related polynucleotides to mammalian cells, whether in vitro or in vivo, to inhibit the endogenous expression of PTTG. Other embodiments are directed to peptide-based treatments that deliver PTTG-C peptide molecules to the cells, which inhibit endogenous PTTG expression and/or PTTG function. The method can also enhance the effectiveness of cytotoxic chemotherapeutic agents conventionally used to treat breast or ovarian cancers, thus allowing lower effective doses of the agents to be administered.
Use Of Peroxisome Proliferator Activated Receptor (Ppar)-Gamma Ligands As A Treatment For Pituitary Tumors And Associated Conditions, Such As Cushing's Syndrome
Use Of Peroxisome Proliferator Activated Receptor (Ppar)-Gamma Ligands As A Treatment For Pituitary Tumors And Associated Conditions, Such As Cushing's Syndrome
US Patent:
2003022, Dec 4, 2003
Filed:
Jun 4, 2002
Appl. No.:
10/163053
Inventors:
Anthony Heaney - Los Angeles CA, US
Shlomo Melmed - Los Angeles CA, US
Shlomo Melmed - Los Angeles CA, US
International Classification:
A61K031/4439, A61K031/426
US Classification:
514/342000, 514/369000
Abstract:
Disclosed is a method for treating a pituitary tumor in a mammal, employing the administration of a peroxisome proliferator activated receptor gamma ligand (also known as “peroxisome proliferating-activator receptor gamma” or “PPAR-”). In some embodiments, the peroxisome proliferator activated receptor gamma ligand is a thiazolidinedione compound. Also disclosed are methods for preventing the formation of a pituitary tumor in a mammal and for preventing the recurrence of a pituitary tumor in a mammal. Further disclosed is a method for treating a mammal exhibiting one or more symptoms of Cushing's syndrome.
Method Of Regulating Biological Activity Of Pituitary Tumor Transforming Gene (Pttg)1 Using Pttg2
Method Of Regulating Biological Activity Of Pituitary Tumor Transforming Gene (Pttg)1 Using Pttg2
US Patent:
6913926, Jul 5, 2005
Filed:
May 11, 2001
Appl. No.:
09/854326
Inventors:
Toni Rita Prezant - West Hills CA, US
Anthony P. Heaney - Los Angeles CA, US
Shlomo Melmed - Los Angeles CA, US
Anthony P. Heaney - Los Angeles CA, US
Shlomo Melmed - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
C12N015/63, C12N015/00, A01N063/00, C07H021/04
US Classification:
435455, 4353201, 424 932, 424 9321, 536 235, 536 241
Abstract:
Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian breast or ovarian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a pituitary tumor transforming gene (PTTG)2 peptide, which has the ability to regulate endogenous PTTG1 expression and/or function in a dominant negative manner. In some embodiments, the invention is directed to gene-based treatments that deliver PTTG2-encoding polynucleotides to mammalian cells, whether in vitro or in vivo, to inhibit the endogenous expression of PTTG1. Other embodiments are directed to peptide-based treatments that deliver PTTG2 peptide molecules to the cells, which inhibit endogenous PTTG1 expression and/or PTTG1 function. Kits useful in practicing the inventive method are also disclosed.
Transgenic Cells Transfected With Pituitary Tumor Transforming Gene (Pttg)) Expression Vectors And Uses Therefor
Transgenic Cells Transfected With Pituitary Tumor Transforming Gene (Pttg)) Expression Vectors And Uses Therefor
US Patent:
7097829, Aug 29, 2006
Filed:
Oct 4, 2002
Appl. No.:
10/264372
Inventors:
Anthony P. Heaney - Los Angeles CA, US
Shlomo Melmed - Los Angeles CA, US
Shlomo Melmed - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
A01N 63/00, C12N 15/00, C12N 15/63, C07H 21/04
US Classification:
424 9321, 424 932, 4353201, 435455, 536 235
Abstract:
Described are cells transfected with expression vectors containing pituitary tumor transfer gene (PTTG) and uses therefor. The PTTG nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences, and/or may be carried by a host cell. The host cell may be a thyroid stimulating hormone (TSH)-sensitive cell transfected with an expression vector comprising a DNA segment encoding functional PTTG, wherein the cell overexpresses PTTG in response to TSH. Also described is an in vitro cell model used to study biological processes mediated by PTTG and a method for evaluating a compound for its ability to modulate PTTG expression.
Use Of Fructose-Based Therapies For The Treatment Of Cancer
Use Of Fructose-Based Therapies For The Treatment Of Cancer
US Patent:
2009023, Sep 17, 2009
Filed:
Aug 24, 2006
Appl. No.:
12/064491
Inventors:
Anthony P. Heaney - Los Angeles CA, US
Hongxiang Hui - Los Angeles CA, US
Hongxiang Hui - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61K 51/06, A61P 35/00, A61K 31/713, A61K 31/70, A61K 39/385, A61K 31/51, A61K 101/00, A61K 101/02, A61K 103/00, A61K 103/10, A61K 103/20, A61K 103/30
US Classification:
424 173, 514 44 A, 514 23, 4242361, 514276
Abstract:
The methods and compositions of the invention are based on the preferential utilization of fructose by cancer cells. This invention relates to compositions, methods and kits utilizing fructose and other monosaccharides for the treatment of cancer. This invention also relates to methods and kits for using compositions to mimic or corrupt metabolic pathways of fructose and/or signal transduction pathways related to cancer cells for the treatment of cancer.
Methods Of Modulating Angiogenesis By Regulating The Expression Of Pituitary Tumor Transforming Gene (Pttg)
Methods Of Modulating Angiogenesis By Regulating The Expression Of Pituitary Tumor Transforming Gene (Pttg)
US Patent:
2002014, Oct 10, 2002
Filed:
Feb 5, 2001
Appl. No.:
09/777422
Inventors:
Anthony Heaney - Los Angeles CA, US
Hiroki Ishikawa - Nagasaki, JP
Run Yu - Los Angeles CA, US
Gregory Horwitz - Los Angeles CA, US
Xun Zhang - Malden MA, US
Shlomo Melmed - Los Angeles CA, US
Hiroki Ishikawa - Nagasaki, JP
Run Yu - Los Angeles CA, US
Gregory Horwitz - Los Angeles CA, US
Xun Zhang - Malden MA, US
Shlomo Melmed - Los Angeles CA, US
International Classification:
A61K031/70, A01N043/04
US Classification:
514/044000
Abstract:
Disclosed is a method of modulating angiogenesis in a tissue comprising mammalian cells, including cells of human origin, in vitro or in vivo. Also disclosed are a method of enhancing wound healing and/or tissue regeneration and a method of limiting scar formation.
Use Of Fructose-Based Compounds For The Diagnosis Of Cancer
Use Of Fructose-Based Compounds For The Diagnosis Of Cancer
US Patent:
8241607, Aug 14, 2012
Filed:
Aug 24, 2006
Appl. No.:
12/064496
Inventors:
Anthony P. Heaney - Los Angeles CA, US
Hongxiang Hui - Los Angeles CA, US
Alan Waxman - Manhattan Beach CA, US
Hongxiang Hui - Los Angeles CA, US
Alan Waxman - Manhattan Beach CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
A61K 49/00
US Classification:
424 91, 424 111, 424 165, 424 173, 424 189
Abstract:
This invention relates to compositions, methods utilizing fructose and other monosaccharides for the diagnosis of cancer. Cancer cells have shown a higher level of fructose utilization as compared to glucose. Further, cancer cells have shown a preferential use of fructose for nucleic acid synthesis. The present invention takes advantage of these features and provides for fructose or fructose-based compositions for the diagnosis of cancer using imaging techniques such as positron emission tomography.